sales@scalarmarketresearch.com |  +1-800-213-5170  (U.S./ Canada Toll-free) |  REGISTER |  SIGN IN

Home >> Reports >> gastrointestinal drugs market

report

Gastrointestinal Drugs Market, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Antiemetic, Anti-inflammatory drugs), Route of Administration (Oral, Parenteral, Rectal), Disease Type (Gastro esophageal Reflux Disease, Inflammatory Bowel Disease), End user (Hospital Pharmacies, Retail Pharmacies) – Global Revenue, Trends, Growth, Share, Size and Forecast to 2022

HC352 August 2017 100+ FREE 10% CUSTOMIZATION

Gastrointestinal mostly affect body parts like stomach, small intestine, large intestine, gall bladder, pancreas and rectum. The diseases can affect any group of people, but mostly occur in old aged population when the digestive track starts to weaken. Improper digestion, heartburn, gases, and inflammation are some of the basic symptoms of gastrointestinal diseases. This report studies the current and future aspects of gastrointestinal drugs market.

The report on the global Gastrointestinal drugs market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The report also tracks the emerging applications, innovative technologies, and mergers & acquisitions. It also focuses on the growth drivers and restraints for the key market players during the forecast period.

KEY BENEFITS OF THE REPORT

  • In-depth analysis of the market ecosystem and its impact on the revenue growth
  • Understanding of the strategies that are being adopted by the key players in this market to stay competitive
  • Valuable insights into the key technological and market trends impacting this market

KEY PREMIUM INDUSTRY INSIGHTS

  • Major factor driving the gastrointestinal drugs market is the rise in occurrence of gastrointestinal diseases. Pharmaceutical companies of developed as well as developing countries are investing heavily in research and development activities and working on improving the efficacy of the drugs, thereby increasing the growth opportunities of the market.
  • Companies are collaborating and entering into a partnership which is also one of the factors contributing towards growth of the gastrointestinal drugs market. In addition, advancement in technology is boosting the global market growth.
  • With the rise in geriatric population and changes in lifestyle, the incidences of gastrointestinal diseases are explicitly increasing which is paving way to the growth of global gastrointestinal drugs market.

The gastrointestinal drugs market is divided into four major geographical segments which are North America, Europe, Asia-Pacific, and Rest of the world. The North America region holds the highest market share and is the largest revenue contributor of the gastrointestinal drugs market. The region continues to dominate the global market due to increase in geriatric population and rise in number of chronic diseases. With rise in number of elderly people in the North America region, the market is estimated to grow at a steady pace and remain a dominant region during the forecasted period. Next in line is the Europe region which is witnessing a rapid growth due to availability of biosimilars for the treatment of bowel disorders. Asia-Pacific region is also gaining pace due to increase in population and rise in investment by public and private organizations for promoting the technological advancements related to the treatment options of gastrointestinal diseases.

RESEARCH METHODOLOGY

The research methodology for Scalar Market Research’s gastrointestinal drugs market report utilizes a combination of top-down and bottom-up research formats. Our primary focus on continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensures high-quality data that can be leveraged for actionable research insights.

To know about the assumptions considered for the study, Download PDF Sample.

MARKET SEGMENTATION

This report analyzes the gastrointestinal drugs market by the following segments:

  • Gastrointestinal Drugs Market, by Drug Category
    • Acid Neutralizers,
    • Laxatives and Antidiarrheal
    • Antiemetic
    • Anti-inflammatory drugs
    • Other
  • Gastrointestinal Drugs Market, by Route of Administration
    • Oral
    • Parenteral
    • Rectal
  • Gastrointestinal Drugs Market, by Disease
    • Gastro esophageal Reflux Disease,
    • Inflammatory Bowel Disease
    • Other
  • Gastrointestinal Drugs Market, by End User
    • Hospital Pharmacies
    • Retail Pharmacies
    • Other

KEY MARKET PLAYERS

Key players in the gastrointestinal drugs market include:

  • AbbVie Inc.
  • AstraZeneca
  • Johnson & Johnson
  • Valeant
  • Abbott Laboratories
  • Allergan Plc
  • Bayer AG
  • Janssen Biotech Inc.
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Valeant Pharmaceuticals

GEOGRAPHIC COVERAGE AND ANALYSIS

This granular market research report covers the following geographic regions in great detail:

  • NORTH AMERICA
    • U.S.
    • Rest of North America
  • EUROPE
    • France
    • Germany
    • U.K
    • Rest of Europe
  • ASIA-PACIFIC
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • REST OF THE WORLD
    • Latin America
    • Middle East & Africa

TRENDING RELATED REPORT

Gastrointestinal Diseases Market, by Drug Category (Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Anti-diarrhoea and Other GIT Therapeutics) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022


  1. MARKET OVERVIEW
    1. Market Definitions
    2. Research Methodology
    3. Market Segmentation
  2. EXECUTIVE SUMMARY
  3. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Premium Industry Trends
  4. INDUSTRY ANALYSIS
    1. Value Chain Analysis
    2. Technology Roadmap
  5. GASTROINTESTINAL DRUGS MARKET, BY DRUG CATEGORY
    1. Segment Share
    2. By Drug Category
      1. Acid Neutralizers,
      2. Laxatives and Antidiarrheal
      3. Antiemetic
      4. Anti-inflammatory drugs
      5. Other
  6. GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
    1. Segment Share
    2. By Route of Administration
      1. Oral
      2. Parenteral
      3. Rectal
  7. GASTROINTESTINAL DRUGS MARKET, BY DISEASE
    1. Segment Share
    2. By Disease
      1. Gastro esophageal Reflux Disease,
      2. Inflammatory Bowel Disease
      3. Other
  8. GASTROINTESTINAL DRUGS MARKET, BY END USER
    1. Segment Share
    2. By End-user
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Other
  9. GASTROINTESTINAL DRUGS MARKET, BY GEOGRAPHY
    1. Segment Share
    2. North America
      1. By Regions
        1. U.S.
        2. Rest of North America
      2. By Drug Category
      3. By Route of Administration
      4. By Disease
      5. By End-user
    3. Europe
      1. By Regions
        1. France
        2. Germany
        3. U.K.
        4. Rest of Europe
      2. By Drug Category
      3. By Route of Administration
      4. By Disease
      5. By End-user
    4. Asia-Pacific
      1. By Regions
        1. China
        2. India
        3. Japan
        4. Rest of Asia-Pacific
      2. By Drug Category
      3. By Route of Administration
      4. By Disease
      5. By End-user
    5. Rest of the World
      1. By Regions
        1. Latin America
        2. Middle East & Africa
      2. By Drug Category
      3. By Route of Administration
      4. By Disease
      5. By End-user
  10. COMPETITIVE LANDSCAPE
    1. Market Positioning of Key Players, 2016
    2. Key Innovators
  11. KEY MARKET PLAYERS
    1. AbbVie Inc.
      1. Overview
      2. Key Strategies
      3. Key Development
    2. AstraZeneca
      1. Overview
      2. Key Strategies
      3. Key Developments
    3. Johnson & Johnson
      1. Overview
      2. Key Strategies
      3. Key Developments
    4. Valeant
      1. Overview
      2. Key Strategies
      3. Key Developments
    5. Abbott Laboratories
      1. Overview
      2. Key Strategies
      3. Key Developments
    6. Allergan Plc
      1. Overview
      2. Key Strategies
      3. Key Developments
    7. Bayer AG
      1. Overview
      2. Key Strategies
      3. Key Developments
    8. Janssen Biotech Inc.
      1. Overview
      2. Key Strategies
      3. Key Developments
    9. Takeda Pharmaceutical Company Limited
      1. Overview
      2. Key Strategies
      3. Key Developments
    10. Eisai Co., Ltd.
      1. Overview
      2. Key Strategies
      3. Key Developments
    11. Valeant Pharmaceuticals
      1. Overview
      2. Key Strategies
      3. Key Developments
  12. SCALAR 360 DEGREE MARKET PERSPECTIVE
  13. APPENDIX
Please submit your enquiry below so our representative can get in touch with you
*
*
*
*
*
*

USA - CANADA TOLL FREE
+1-800-213-5170

EMAIL
sales@scalarmarketresearch.com

Benefits of Buying From Scalar

Unparalleled Expertise

Our industry experts hold inimitable know-how across wide range of industry verticals

Assured Quality

We deliver high-quality, real-time and data-driven industry insights to our clients

24x7 Analyst Support

We offer pre-purchase and post-purchase support from our industry experts

Privacy & Security

All your personal information and confidential details are safe and secure with us